Citigroup’s Jasper Therapeutics JSPR Stock Holding History

Citigroup’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-642	Closed	-$1.18K	–	6172
2025 Q4	$1.18K	Buy	+642	New	+$1.29K	﹤0.01%	5531
2025 Q2	–	Sell	-8,057	Closed	-$34.6K	–	5784
2025 Q1	$34.6K	Sell	8,057 -1,003	-11%	-$6.67K	﹤0.01%	4981
2024 Q4	$194K	Buy	9,060 +895	+11%	+$18.6K	﹤0.01%	4435
2024 Q3	$154K	Buy	8,165 +5,702	+232%	+$114K	﹤0.01%	4536
2024 Q2	$55.9K	Sell	2,463 -4,900	-67%	-$118K	﹤0.01%	4513
2024 Q1	$216K	Buy	+7,363	New	+$131K	﹤0.01%	3988
2023 Q2	–	Sell	-6,481	Closed	-$117K	–	5652
2023 Q1	$117K	Buy	+6,481	New	+$120K	﹤0.01%	3961
2022 Q3	–	Sell	-20	Closed	–	–	6088
2022 Q2	$0	Buy	+20	New	+$570	﹤0.01%	6442
2021 Q3	–	Sell	-2,000	Closed	-$199K	–	6057
2021 Q2	$199K	Hold	2,000	–	–	﹤0.01%	4238
2021 Q1	$199K	Hold	2,000	–	–	﹤0.01%	4014
2020 Q4	$200K	Hold	2,000	–	–	﹤0.01%	4985
2020 Q3	$198K	Buy	+2,000	New	+$200K	﹤0.01%	4623

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Citigroup's JSPR Position: Q1 2026 in Review

Citigroup sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 642 shares — an estimated $1.18K sold.

Citigroup first reported a position in JSPR in Q3 2020 and held it in 12 quarters. The position peaked at $216K in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Citigroup reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
Citigroup sold 642 Jasper Therapeutics shares in Q1 2026, an estimated $1.18K.
Citigroup first reported a position in Jasper Therapeutics in Q3 2020 and held it in 12 quarters.
Citigroup's Jasper Therapeutics position peaked at $216K in Q1 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.